Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/13/2026, 12:00:00 AM
The U.S. FDA granted Priority Review for the Biologics License Application for ifinatamab deruxtecan for a type of small cell lung cancer on April 13, 2026. The PDUFA action date is set for October 10, 2026.
Korean Translation
미국 FDA, 2026년 4월 13일 소세포폐암 치료제 이피나타맙 데룩스테칸의 생물의약품 허가 신청에 대한 우선 심사를 승인함. 처방의약품 신청자 수수료법(PDUFA)에 따른 결정일은 2026년 10월 10일임.
Related Recent Events
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to release its Q1 2026 earnings report before the market opens on May 6, 2026, with high importance estimated due to potential 10% price impact, expected.
5/6/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Earnings Release
Life Time Group Holdings is scheduled to report its Q1 2026 financial results. A moderate market reaction is estimated for this standard earnings release scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, followed by a conference call. High impact is estimated due to significant market focus on GLP-1 sales growth scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is scheduled to release its Q1 2026 earnings on April 30, 2026; impact is estimated as neutral pending the actual report, scheduled.
4/30/2026, 12:00:00 AM
Amgen Inc (AMGN) · Earnings Release
Amgen is expected to report its Q1 2026 financial results after the market closes on April 30, 2026, scheduled. Analysts estimate a Low impact (~1-2%) as a standard scheduled reporting event, scheduled.
4/30/2026, 12:00:00 AM
Astrazeneca PLC (AZN) · Earnings Release
AstraZeneca's Q1 2026 results announcement is scheduled for April 29, 2026 scheduled
4/29/2026, 12:00:00 AM